Your cart

There are no items in your shopping cart

Repaglinide - AG-EE 623ZW

Based on 20 reference(s) in Google Scholar 80 100 20

Axon 3365

CAS [135062-02-1]

MF C27H36N2O4
MW 452.59

  • Purity: 100%
  • Optical purity: Optically pure
  • Soluble in 0.1N NaOH(aq) and DMSO

Repaglinide

Description

Antidiabetic; KATP channel blocker. Repaglinide was found to bind with low affinity (Kd of 59 nM) to SUR1 alone, but with high affinity (increased approximately 150-fold) when SUR1 was co-expressed with Kir6.2 (Kd value of 0.42 nM).

KEYWORDS: Repaglinide | supplier | KATP channel blocker | AG-EE 623ZW | AGEE 623ZW | AG EE 623ZW | CAS [135062-02-1] | Potassium | Kir6.2-SUR1 | Blocker | Ion Channels | Diabetes mellitus

Order
Size Unit Price Stock
50 mg €90.00 In Stock
Special Offers
Size Unit Price Stock
2 x 50 mg €140.00 In Stock
Need more? Bulk Inquiry

Related Products

Axon ID Name Description From price
1274 PNU 37883 hydrochloride K+ channel blocker (ATP sensitive, vascular) €85.00
1647 NN 414 K+ channel opener (SUR1/Kir6.2 selective) €110.00
1757 HMR 1098 K+ channel blocker (SUR1/Kir6.2 selective) €95.00
2064 Glibenclamide potassium salt KATP channel blocker; inhibits SUR1 €50.00
3490 Minoxidil K+ channel opener (ATP sensitive, vascular) €50.00
3641 Nateglinide KATP channel blocker; inhibits SUR1 €60.00
3675 VU6036720 hydrochloride First potent and selective inhibitor of heteromeric Kir4.1/5.1 inward rectifier potassium channels €130.00
3799 VU6036721 hydrochloride Inactive enantiomer of VU6036720 hydrochloride €130.00

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Newsletter
Give Feedback
 
Send E-mail

Customer Support

About Axon Medchem

Download Product Catalog

Download the Axon Ligands™ catalogue 2021 Spring Edition

Follow Us

© 2016 Axon Medchem. All Rights Reserved.

Send us a message

×

Contact Us

* Required Fields

Please wait...